https://ushealthdigest.comEvidence-first reporting on health, weight and telehealth in America.https://ushealthdigest.com/what-are-peptides/https://ushealthdigest.com/what-are-peptides/A peptide is a short chain of amino acids — a chemistry word, not a category of medicine. The same word now covers FDA-approved drugs, supplement-aisle collagen, and gray-market vials labeled 'not for human consumption'. Here is the map, plus the July 2026 FDA compounding fight.2026-07-28https://ushealthdigest.com/bpc-157-evidence-and-legal-status/https://ushealthdigest.com/bpc-157-evidence-and-legal-status/An FDA advisory committee voted 8-6 on July 23, 2026 to recommend BPC-157 for the 503A compounding list. FDA's own reviewers recommended against it. What the human evidence is, what the vote does and does not do, and why BPC-157 is still not an approved drug.2026-07-28https://ushealthdigest.com/oral-glp1-head-to-head-2026/https://ushealthdigest.com/oral-glp1-head-to-head-2026/ACHIEVE-3 pitted orforglipron against oral semaglutide and orforglipron won on A1c and weight — but it was a type 2 diabetes trial, and orforglipron had more GI side effects and twice the discontinuation rate. What that does and does not mean for weight loss.2026-07-28https://ushealthdigest.com/medicare-glp1-bridge-women/https://ushealthdigest.com/medicare-glp1-bridge-women/The Medicare GLP-1 Bridge went live July 1, 2026. Who qualifies, which drugs are covered, how the prescription and prior authorization actually work, and what the $50 copay does and doesn't count toward — sourced to medicare.gov, CMS, and KFF.2026-07-26https://ushealthdigest.com/glp1-teens-young-adults-2026/https://ushealthdigest.com/glp1-teens-young-adults-2026/A JAMA Pediatrics study of 204,000+ patients aged 13–25 finds GLP-1-only treatment rose to 96.1% while bariatric surgery fell to 3.7%. The adolescent evidence, the unknowns, and what to ask a pediatrician.2026-07-26https://ushealthdigest.com/us-obesity-rate-falling-glp1-2026/https://ushealthdigest.com/us-obesity-rate-falling-glp1-2026/Gallup finds US adult obesity at 36.4% in 2026, down from a 39.9% peak, while 1 in 9 adults now take a GLP-1. What the survey shows — and what it can't.2026-07-26https://ushealthdigest.com/glp1-over-40-women/https://ushealthdigest.com/glp1-over-40-women/What GLP-1 trials do and don't establish for women over 40: midlife body composition, lean mass, bone health, maintenance after stopping, and open questions.2026-07-24https://ushealthdigest.com/appeal-glp1-coverage-denial/https://ushealthdigest.com/appeal-glp1-coverage-denial/Denied GLP-1 coverage? Step-by-step guide to internal appeals, external review, and Medicare Part D appeals — deadlines sourced to healthcare.gov and CMS.2026-07-24https://ushealthdigest.com/glp1-vision-risk-naion-2026/https://ushealthdigest.com/glp1-vision-risk-naion-2026/A 2026 meta-analysis and Europe's 2025 label decision tie semaglutide to a very rare optic-nerve condition. The absolute risk in plain numbers, and what to do.2026-07-24https://ushealthdigest.com/oral-glp1-pills-2026/https://ushealthdigest.com/oral-glp1-pills-2026/Two FDA-approved GLP-1 pills now exist: oral Wegovy (semaglutide 25 mg) and Foundayo (orforglipron). What the OASIS 4 and ATTAIN-1 trials found, how the pills compare with injections, and why the 'oral semaglutide kits' sold online are neither.2026-07-22https://ushealthdigest.com/glp1-insurance-coverage-2026/https://ushealthdigest.com/glp1-insurance-coverage-2026/Medicare's new $50/month GLP-1 Bridge program started July 1, 2026. What it covers, how Medicaid varies by state, what employer plans actually do, and a step-by-step checklist to find out where you stand.2026-07-22https://ushealthdigest.com/fda-compounded-glp1-ban-2026/https://ushealthdigest.com/fda-compounded-glp1-ban-2026/The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from large-scale compounding. The comment period, extended once, closes July 30, 2026. What's proposed vs. final — and what to do if you're on a compounded program.2026-07-22https://ushealthdigest.com/semaglutide-results-women/https://ushealthdigest.com/semaglutide-results-women/The real numbers behind semaglutide weight loss for women — average results, timelines and side effects from the pivotal STEP 1 trial, without the marketing gloss.2026-07-21https://ushealthdigest.com/compounded-vs-branded-glp1-2026/https://ushealthdigest.com/compounded-vs-branded-glp1-2026/The compounded semaglutide crackdown explained — what changed in 2025-2026, what's still legal, and what it means if you're taking or considering a compounded GLP-1.2026-07-21https://ushealthdigest.com/glp1-faq-women/https://ushealthdigest.com/glp1-faq-women/Results, costs, side effects, safety, the compounding crackdown and how to choose a telehealth program — the complete evidence-cited GLP-1 FAQ for women.2026-07-21https://ushealthdigest.com/best-glp1-telehealth-programs-women-2026/https://ushealthdigest.com/best-glp1-telehealth-programs-women-2026/Seven real GLP-1 telehealth programs compared for women — branded vs compounded medication, clinical oversight, pricing models, and the trade-offs the cheap options don't advertise.2026-07-21https://ushealthdigest.com/glp1-cost-without-insurance-2026/https://ushealthdigest.com/glp1-cost-without-insurance-2026/A sober breakdown of what GLP-1 weight-loss treatment actually costs without insurance in 2026 — branded cash prices, manufacturer direct-pay programs, compounded offers, and the questions to ask before any price looks like a bargain.2026-07-21https://ushealthdigest.com/wegovy-vs-zepbound-women/https://ushealthdigest.com/wegovy-vs-zepbound-women/Semaglutide (Wegovy) vs tirzepatide (Zepbound) for women: what the STEP 1, SURMOUNT-1, and head-to-head SURMOUNT-5 trials actually found on weight loss, side effects, and cost trade-offs.2026-07-21https://ushealthdigest.com/how-glp1-telehealth-works/https://ushealthdigest.com/how-glp1-telehealth-works/The six steps of a GLP-1 telehealth program — intake, clinician review, prescription, pharmacy shipping, dose escalation, and renewals — with the legitimate version and the red-flag version of each.2026-07-21https://ushealthdigest.com/glp1-statistics-2026/https://ushealthdigest.com/glp1-statistics-2026/The key GLP-1 statistics in one place: how many Americans use them, what the trials show, discontinuation and regain data, and the compounding crackdown — each number linked to its primary source.2026-07-21